![]() |
|
|
B Activation by Interacting Preferentially with the I
B Kinase
Subunit
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Received October 31, 2003; accepted March 1, 2004
| Abstract |
|---|
|
|
|---|
B is known to be a critical transcription factor in inflammatory responses. We have reported that herbimycin A, a potent Src tyrosine kinase inhibitor, attenuates the NF-
B activation triggered by cytokines, bacterial endotoxin, and hydrogen peroxide. Accompanying the suppression by this agent, NF-
B-dependent gene expressions, such as cytokine, chemokine, and inducible-type nitric oxide, are specifically inhibited in glial cells. In the present study, we attempted to elucidate the possible target protein for herbimycin A on this pathway. We demonstrate here that herbimycin A preferentially inhibits IKK (I
B kinase)
. Furthermore, substituting alanine for the cysteine at 59 (Cys59) in IKK
resulted in the insensitivity to herbimycin A, suggesting that this compound may interact with the Cys59 residue located near the catalytic ATP binding site. Taken together, these results indicate that herbimycin A can be considered a novel candidate for an anti-inflammatory drug agent through its specific inhibition of IKK
, which results in prevention of the expression of NF-
B-dependent genes implicated in the pathogenesis of inflammatory responses.
B plays several essential roles in the inducible gene expression that contribute to a diverse range of biological processes (e.g., development, immune, and inflammatory responses) (Baeuerle and Baltimore, 1996
B is sequestered in the cytoplasm as an inactive form because of its association with I
B
protein. After a variety of extracellular stimuli, such as tumor necrosis factor (TNF)
and interleukin (IL)-1
, I
B
is phosphorylated specifically (Ser32 and Ser36) by I
B kinases (IKKs) (DiDonato et al., 1997
B
allows NF-
B to translocate to the nucleus, where it activates the transcription of specific target genes (Perkins, 2000
700 to 900-kDa protein complexes consisting of at least two catalytic subunits, IKK
and IKK
, and a regulatory subunit, NF-
B essential modulator (also known as IKK
/IKKAP1) (Rothwarf et al., 1998
and IKK
are two highly homologous kinases, both containing a conserved N-terminal kinase domain and a C-terminal region with a leucine zipper (LZ) and a helix-loop-helix motif (Karin, 1999a
and IKK
, both the LZ and helix-loop-helix motifs are important for modulating the kinase activities of IKK
/
(Karin, 1999b
/
dimers are phosphorylated at Ser176 and Ser180 in IKK
or Ser177 and Ser181 in IKK
by NF-
B-inducing kinase (NIK) (Malinin et al., 1997
signaling pathway that may be activated by cytoplasmic adaptor proteins, such as ribosome inactivating proteins or TRAF2 (Malinin et al., 1997
/
with receptor signalsomes, such as TNFR, IL-1R, and TLR4. Overexpression of wild-type NIK potently activates NF-
B, whereas a catalytically inactive NIK mutant dominantly interferes with TNF
- and IL-1
-induced NF-
B activation (Malinin et al., 1997
We have reported previously that herbimycin A, a potent Src tyrosine kinase inhibitor, suppresses the NF-
B activation and subsequent induction of inducible nitric oxide synthase and chemokines by treatment with several stimuli in C6 glioma cells (Uehara et al., 1989
, 1998
, 1999
; Nishiya et al., 1995
, 2000
). However, the target molecule of herbimycin A in NF-
B-activating pathways remains to be identified. In this study, we attempted to elucidate the target protein for herbimycin A. Our results show that herbimycin A selectively inhibits IKK
through the possible interaction with cysteine 59, which is located near the catalytic site in the kinase domain in IKK
. We concluded that herbimycin A is a novel potent inhibitor of IKK
in NF-
B signaling.
| Materials and Methods |
|---|
|
|
|---|
(M-280), anti-IKK
(H-4), anti-I
B
(C-21), and anti-NF-
B (p65) antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-phospho I
B
(Ser32) and phospho IKK
(Ser180)/
(Ser181) antibodies were purchased from New England Biolabs (Beverly, MA). Herbimycin A was obtained from Wako Pure Chemicals (Osaka, Japan).
Expression Vectors and Site-Directed Mutagenesis. FLAG epitope-tagged NIK, NIK (K429A/K430A) mutant, IKK
(K44A) mutant, and IKK
(K44A) mutant were generous gifts from Dr. David V. Goeddel (Tularik Inc., South San Francisco, CA). NIK and IKKs were subcloned into pRK vector. Several mutants of NIK, IKK
, and IKK
were generated by the overlapping PCR method. To clarify the possible modification site with herbimycin A in IKK, variants of IKK
and IKK
were prepared by PCR. In addition, seven cysteine residues in the kinase domain of IKK were displaced with an alanine residue by the overlapping PCR method.
Transfection, Immunoprecipitation, and Immunoblotting Analyses. HEK 293 T cells were transiently transfected with expression plasmids (8 µg each) by the calcium phosphate method. After 36 h, cells were washed twice with cold PBS and lysed in lysis buffer [50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1% NP40, and the Complete protease inhibitors (Roche Molecular Biochemicals, Indianapolis, IN)]. Immunoprecipitation and immunoblotting analyses were performed as described previously (Ko et al., 2002
). In brief, the total cell lysate was centrifuged at 15,000 rpm for 30 min at 4°C. The supernatant was incubated with protein G-Sepharose for 1 h at 4°C and then centrifuged for 10 min. The resultant supernatant was incubated for 16 h with the first antibody, which had been precoupled with protein G-Sepharose. The immunoprecipitates were washed twice with lysis buffer and three times with washing buffer (50 mM Tris/HCl, pH 7.5, 137 mM NaCl, 1 mM EGTA, 1 mM vanadate, and 0.1% Triton X-100). Otherwise, cells were washed twice with ice-cold PBS and added to the SDS sample buffer. Protein (20 µg) from the lysate was fractionated by electrophoresis in 10% polyacrylamide gel and transferred onto a nitrocellulose membrane. Horseradish peroxidase-conjugated anti-mouse or -rabbit IgG (Amersham Biosciences Inc., Piscataway, NJ) was used as the secondary antibody. The antibody-reactive bands were revealed by chemiluminescent detection (enhanced chemiluminescence Western detection kit).
Reporter Assays. For the reporter assays, cells were transfected with 0.25 µg pNF-
B Luc vector (BD Biosciences Clontech, Palo Alto, CA) and 1.25 ng of pRL-TK (internal control plasmid). Reporter gene activity was determined with the luciferase assay system (Promega, Madison, WI). In particular, to confirm the possible target site for herbimycin A, Hs683 glial cells were transfected with 5 µg of C59A-mutated IKK
together with pNF-
B Luc and pRL-TK vectors. The cells were treated with or without herbimycin A and then stimulated with 5.0 ng/ml IL-1
for 6 h.
Immunohistochemistry. To analyze the localization of NF-
B (p65 subunit), we used human Hs683 glioma cells transiently transfected with several genes. Cells were fixed in 4% paraformaldehyde, permeabilized in 0.5% Triton X-100, and incubated with anti-NF-
B (1:100 dilution) and anti-phospho IKK (1:100 dilution) antibodies for 1 h at 37°C. After reaction with the first antibody, cells were incubated with anti-mouse IgG conjugated with Alexa-488, anti-goat IgG conjugated with Alexa-488, and anti-rabbit IgG conjugated with Alexa-594 (Molecular Probes, Eugene, OR) for 1 h at 37°C. All images were taken on a laser-scanning confocal microscope (LSM510; Carl Zeiss Inc., Thornwood, NY) (Tanaka et al., 2000
; Furuta et al., 2003
).
In vitro Kinase Assay. HEK 293 cells were transfected with wild-type IKK
and then incubated for 36 h. The cells were washed rapidly with PBS and lysed with ice-cold lysis buffer, after which IKK
was immunoprecipitated. The immunoprecipitated IKK
with protein G-Sepharose beads was collected by centrifugation, then washed three times with lysis buffer and once with kinase assay buffer without ATP. The immunoprecipitates were then suspended in 20 µl of kinase assay buffer (20 mM Tris-HCl, pH 7.6, 10 µM MgCl2, 100 µM ATP, and 20 µM
-glycerophosphate) containing 5 µCi [
-32P]ATP and 1 µgofI
B
as substrate with or without several concentrations of herbimycin A for 20 min at 25°C. The reaction was stopped by the addition of Laemmli buffer, the proteins were separated by electrophoresis on 10% SDS-PAGE, and phosphorylated I
B
was visualized by autoradiography or on a Fuji BAS2000 apparatus (Tokyo, Japan). Quantitative data were obtained from Fuji BAStation software.
| Results |
|---|
|
|
|---|
B Activation. We initially examined the inhibitory effect of herbimycin A on IL-1
-stimulated reporter gene expression and translocation of the NF-
B p65 subunit. Herbimycin A alone (1 µg/ml) did not affect the NF-
B activity in this system (data not shown). As shown in Fig. 1A, treatment of human Hs683 glioma cells with herbimycin A resulted in a dose-dependent decrease in the NF-
B activity detected by luciferase assay. Immunohistochemical analysis revealed that the NF-
B p65 subunit was localized mostly in the cytosol in the quiescent state and translocated to the nucleus at 15 to 30 min after IL-1
treatment. After 60 min, p65 returned to the cytosol (Fig. 1B). Herbimycin A inhibited completely the translocation of p65 induced by IL-1
treatment.
|
Effects of Herbimycin A on Phosphorylation of IKK and I
B
To identify the target molecule for herbimycin A, we investigated the phosphorylation states of I
B
by overexpressing several genes, such as wild types and kinase-negative mutants of NIK, IKK
, and IKK
with or without herbimycin A. Transfection of the wild types of NIK and IKK
, but not IKK
, resulted in significant phosphorylation of I
B
in a herbimycin A-sensitive manner (Fig. 2A). These results suggest strongly that both NIK and IKK
, but not IKK
, play a crucial role in NF-
B activation. It has been reported previously that transfection of IKK
or IKK
alone into cells results in the formation of a homodimer (Karin, 1999a
,b
). However, IKK
and IKK
exist as heterodimers in cells. Therefore, we examined the effect of herbimycin A on simultaneous cotransfection of IKK
and IKK
. Although no phosphorylation of IKK
and I
B
was observed by transfection of IKK
alone, cotransfection of IKK
plus IKK
resulted in a marked phosphorylation of IKK
(Fig. 2B). Under this condition, the phosphorylation of IKK and I
B
was attenuated by herbimycin A in a concentration-dependent manner (Fig. 2B). NIK alone also induced the phosphorylation of IKK
, IKK
, and I
B
(Fig. 2C). It was interesting that IKK
phosphorylation by NIK transfection was insensitive to herbimycin A. Specific phosphorylation of I
B
by overexpression of NIK was abrogated completely by kinase-negative IKK
but not by kinase-negative IKK
(Fig. 2D).
|
Effects of Herbimycin A on the Protein-Protein Interactions in NF-
B Signaling. It is possible that the inhibitory effects described above were a result of the incomplete interaction between signal molecules because of herbimycin A. We therefore investigated whether this compound interferes with the interaction between NIK and IKK or TRAF2. However, neither of these interactions was abrogated by treatment with herbimycin A (Fig. 3, A and B). We further examined the effect of herbimycin A on the binding of recombinant GST-fused IKKs to I
B
. The significant interactions between GST-IKK
or GST-IKK
and I
B
were observed in a herbimycin A-sensitive manner (Fig. 3C).
|
Herbimycin A Blocked the Kinase Activity of IKK
Because overexpression of IKK
, but not IKK
, resulted in the phosphorylation of I
B
(Fig. 2A), we studied the inhibitory effects of herbimycin A on IKK
kinase activity in vitro. We performed an in vitro kinase assay using the immunoprecipitates with an anti-FLAG antibody from FLAG-IKK
-expressing cell lysates and recombinant I
B
as a substrate.
Herbimycin A dose-dependently impaired the phosphorylation of I
B
(Fig. 4).
|
Treatment with DTT Disrupted the Inhibitory Effects of Herbimycin A. Because the reducing agents, such as dithiothreitol (DTT), inactivate the reaction of herbimycin A with substrate protein (Senga et al., 2000
), we investigated the effects of simultaneous treatment with herbimycin A and DTT on IL-1
-induced phosphorylation of I
B
. Treatment with DTT alone did not affect the state of I
B
phosphorylation compared with that of nontreatment cells. On the other hand, the protein levels of I
B
detected with anti-I
B
antibody were decreased in samples in which the phosphorylation of I
B
was evident. Although herbimycin A completely disrupted the I
B
phosphorylation stimulated by IL-1
, treatment with DTT recovered the inhibitory effect (Fig. 5).
|
In addition, we examined the effects of N-acetyl cysteine (NAC) as an another thiol compound. NAC is known to be a potent inhibitor on the NF-
B pathway (Schreck et al., 1991
; Hayakawa et al., 2003
). High concentrations of NAC (more than 10 mM) are usually required to inhibit this pathway, but this condition was cytotoxic to cells in our system (data not shown). Hence, we could not detect the significant inhibition of NF-
B activation or the phosphorylation of IKKs and I
B
caused by challenge with IL-1 or overexpression of several genes.
Herbimycin A Selectively Affected IKK
Cys59 Near the Catalytic Site. It is possible that herbimycin A interacts with or modifies IKK
and thereby inhibits the NF-
B pathway. In this study, we constructed variants of IKK
to clarify the possible modification site(s). Each of the seven cysteine residues in the kinase domain of IKK
was displaced with an alanine residue (Fig. 6A). Each mutant was transfected transiently, and we then investigated the change in sensitivity of herbimycin A on IKK and I
B
phosphorylation. None of the variants altered the intrinsic kinase activities (Fig. 6B). However, herbimycin A effectively inhibited the phosphorylation in all mutant-transfected cells, with the exception of the C59A mutant of IKK
, which showed insensitivity for herbimycin A. Although IKK
has a structure similar to that of IKK
(Fig. 6A), significant phosphorylation of IKK
and I
B
was not observed in IKK
-transfected cells (Fig. 2A).
|
The C59A Mutant of IKK
Was Insensitive to Herbimycin A. Next, we attempted to characterize the herbimycin A-insensitive C59A IKK
mutant. Immunohistochemical analysis revealed that the wild type or C59A IKK
induced their own phosphorylation in a herbimycin A-sensitive or -insensitive manner, respectively (Fig. 7A). It has been well established that activation of IKK is dependent on phosphorylation of the IKK
subunit and that IKK
is not implicated in IKK activation (Delhase et al., 1999
; Karin, 1999b
; O'Mahony et al., 2000
). However, endogenous IKK complexes are composed of IKK
·IKK
heterodimers. Therefore, we attempted to characterize the effect of the C59A mutant in heterodimers against herbimycin A. As shown in Fig. 2B, coexpression of IKK
and IKK
induced the phosphorylation of IKK
, IKK
, and I
B
in a herbimycin A-sensitive manner. Next, we checked the effect of herbimycin A on IKK
and IKK
phosphorylation in cells transfected by both IKK
and C59A-mutated IKK
. Treatment with herbimycin A disrupted the phosphorylation in wild-type IKK
/IKK
-transfected cells but did not alter the phosphorylation in wild-type IKK
- and mutated C59A IKK
-transfected cells (Fig. 7C). Last, we examined whether the IKK
C59A mutant abrogates NF-
B activation challenged with IL-1
in glioma cells. As shown in Fig. 7D, treatment with herbimycin A resulted in a decrease in NF-
B activity as detected by the luciferase assay in mock-transfected cells. It is noteworthy that the cells overexpressed by the C59A mutant of IKK
showed significant insensitivity to herbimycin A.
|
| Discussion |
|---|
|
|
|---|
B in glial cells (Nishiya et al., 1995
B signaling upstream of I
B
. The I
B
phosphorylation by transfection of wild-type NIK or IKK
, but not of wild-type IKK
, was sensitive to herbimycin A (Fig. 2A). Moreover, we indicate here that 1) NIK alone stimulates phosphorylation of IKKs and subsequently, I
B
, but phosphorylation of IKK
and IKK
is inhibited completely and partially, respectively, by herbimycin A treatment (Fig. 2C); 2) transfection of IKK
together with IKK
stimulates phosphorylation of I
B
and IKKs themselves in a herbimycin A-sensitive manner (Fig. 2B); and 3) NIK-induced phosphorylation of I
B
occurs via IKK
but not IKK
(Fig. 2D). From these observations, we conclude that 1) NIK induces both IKK
and IKK
phosphorylation and the subsequent I
B
phosphorylation and 2) IKK
triggers the phosphorylation of itself and IKK
and subsequently, I
B
. Therefore, we assert that IKK
phosphorylation by NIK is inhibited partially by herbimycin A, probably caused by blockage of the pathway from IKK
to IKK
but not from NIK to IKK
(Fig. 2C). Thus, we speculate that herbimycin A may attenuate IKK
activity at least and thereby impair such subsequent reactions as I
B
phosphorylation and NF-
B activation, because NIK is known to activate the IKK upstream of the IKK complex (Woronicz et al., 1997
molecule. It is difficult at present to determine the kinase activity of IKK
in vivo. Because IKK
could not stimulate the phosphorylation of I
B
(NF-
B activation) in vivo, it is hard to characterize the inhibitory effects of herbimycin A on IKK
in our system. Thus, IKK
may also be another target for herbimycin A, although we could not detect the NF-
B activation by overexpression of IKK
. On the other hand, the inhibitory effect of herbimycin A on NF-
B signaling may be based on suppression of the interaction between NIK and the IKK complex. We therefore attempted to confirm the effect of herbimycin A on the interaction between IKK and NIK. However, we could not observe a significant abrogation of these interactions (Fig. 3A). On the other hand, I
B
interacted with IKK
more tightly than did IKK
in vitro, and the interaction between I
B
and IKK
was attenuated slightly by treatment with herbimycin A (Fig. 3C). These results suggested that herbimycin A achieved its effect through inhibition of both IKK
kinase activity and the interaction between IKK and I
B
.
Herbimycin A has been isolated as a potent selective inhibitor of v-Src tyrosine kinase (Uehara et al., 1989
). This inhibition occurs via the irreversible binding of herbimycin A to a particular Cys residue in the C-terminal of v-Src (Uehara et al., 1989
; Fukazawa et al., 1994
; Senga et al., 2000
). We also observed that herbimycin A blocked IKK
activity dose dependently both in vivo and in vitro, and this effect disappeared with simultaneous addition of DTT (Figs. 2 and 4). Based on the above findings, it seemed possible that IKK
could be covalently modified by herbimycin A at Cys residue(s) localized in or near its kinase domain. We then constructed several variant IKKs with cysteine-to-alanine mutations in their kinase domains. It was surprising that only the C59A mutant showed remarkable resistance against herbimycin A, and the C46A mutant was also less sensitive to this inhibitor than other mutants (Fig. 6B). On the other hand, none of the mutants of IKK
resulted in any change compared with the wild-type IKK
(data not shown). These results suggested strongly that herbimycin A selectively interacted with or modified Cys59 and partly Cys46 in IKK
. These results may have been related to the three-dimensional structure of IKK
or to a disturbance of IKK
by interacting proteins in the IKK complex, such as IKK
or NF-
B essential modulator. In addition, the inhibitory effect of herbimycin A on the IKK
·IKK
heterodimer also disappeared in the cells overexpressing the C59A mutant of IKK
(Fig. 6C). The kinase activity of heterodimerized IKKs was dependent on that of IKK
(Karin, 1999a
,b
). From these observations, it seems possible that herbimycin A binds specifically to IKK
(Cys59 or Cys46) in the IKK complex and thereby inhibits IKK activity. It has been reported previously that prostaglandin A1 and arsenite inhibit the IKK activity caused by binding at Cys178 of IKK
and Cys179 of IKK
, sites that are both located near the kinase activity-regulatory (phosphorylation) sites (Kapahi et al., 2000
; Rossi et al., 2000
). In addition, aspirin, which is used widely as an anti-inflammatory agent, has the ability to inhibit selectively only IKK
activity by interfering competitively with ATP binding (Yin et al., 1998
). Although we cannot currently explain the detailed interactive mechanism of herbimycin A or other compounds on the IKK
molecule, the differences between modification/interaction sites in IKK
by these chemicals may be dependent on their own structure or size. To finish, we attempted to determine whether the IKK
C59A mutant prevents herbimycin A-dependent inhibition of NF-
B activation by IL-1
. As shown in Fig. 7D, the effects of herbimycin A on NF-
B activation triggered by IL-1
disappeared in the C59A mutant-overexpressed cells. From these results, we conclude that Cys59 in IKK
is a target for herbimycin A and consequently, abrogates the NF-
B pathway.
In summary, our results indicate that herbimycin A may interact mainly with the Cys59 of IKK
located in or near the catalytic (ATP binding) site. Therefore, this modification may lead to the inhibition of ATP binding or an interaction with substrate proteins, such as I
B
. In fact, herbimycin A also attenuated the interaction between IKK
and I
B
in vitro (Fig. 3C). Hence, we consider herbimycin A is a potent inhibitor that induces modification specifically at the Cys59 (or Cys46) of IKK
. Based on these findings, herbimycin A may be a useful tool for analysis of NF-
B signaling and could be a new candidate anti-inflammatory drug with a novel function.
| Acknowledgements |
|---|
, and IKK
constructs. | Footnotes |
|---|
S.O. and K.T. contributed equally to this work.
ABBREVIATIONS: NF, nuclear factor; IL, interleukin; GST, glutathione S-transferase; IKK, I
B kinase; LZ, leucine zipper; NIK, NF-
B-inducing kinase; TNF, tumor necrosis factor; DTT, dithiothreitol; TRAF, TNF receptor-associated factor; PCR, polymerase chain reaction; HEK, human embryonic kidney; pRL-TK, Renilla reniformis luciferase reporter plasmid; PAGE, polyacrylamide gel electrophoresis; NAC, N-acetyl cysteine.
Address correspondence to: Prof. Yasuyuki Nomura, Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan. E-mail: nomura{at}pharm.hokudai.ac.jp
| References |
|---|
|
|
|---|
B: ten years after. Cell 87: 13-20.[CrossRef][Medline]
Delhase M, Hayakawa M, Chen Y, and Karin M (1999) Positive and negative regulation of I
B kinase activity through IKK
subunit phosphorylation. Science (Wash DC) 284: 309-313.
DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, and Karin M (1997) A cytokine-responsive I
B kinase that activates the transcription factor NF-
B. Nature (Lond) 388: 548-554.[CrossRef][Medline]
Fukazawa H, Uehara Y, Murakami Y, Mizuno S, Hamada M, and Takeuchi T (1994) Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett 340: 155-158.[CrossRef][Medline]
Furuta Y, Uehara T, and Nomura Y (2003) Correlation between delayed neuronal cell death and selective decrease in phosphatidylinositol 4-kinase expression in the CA1 subfield of the hippocampus after transient forebrain ischemia. J Cereb Blood Flow Metab 23: 962-971.[CrossRef][Medline]
Ghosh S and Karin M (2002). Missing pieces in the NF-
B puzzle. Cell 109: S81-S96.
Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, and Kikugawa K (2003) Evidence that reactive oxygen species do not mediate NF-
B activation. EMBO (Eur Mol Biol Organ) J 22: 3356-3366.[CrossRef][Medline]
Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, and Karin M (2000) Inhibition of NF-
B activation by arsenite through reaction with a critical cysteine in the activation loop of I
B kinase. J Biol Chem 275: 36062-36066.
Karin M (1999a) How NF-
B is activated: the role of the I
B kinase (IKK) complex. Oncogene 18: 6867-6874.[CrossRef][Medline]
Karin M (1999b) The beginning of the end: I
B kinase (IKK) and NF-
B activation. J Biol Chem 274: 27339-27342.
Ko HS, Uehara T, and Nomura Y (2002) Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. J Biol Chem 277: 35386-36392.
Lee FS, Hagler J, Chen ZJ, and Maniatis T (1997) Activation of the I
B
kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88: 213-222.[CrossRef][Medline]
Ling L, Cao Z, and Goeddel DV (1998) NF-
B-inducing kinase activates IKK
by phosphorylation of Ser-176. Proc Natl Acad Sci USA 95: 3792-3797.
Malinin NL, Boldin MP, Kovalenko AV, and Wallach D (1997) MAP3K-related kinase involved in NF-
B induction by TNF, CD95 and IL-1. Nature (Lond) 385: 540-544.[CrossRef][Medline]
Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett B, Li JW, Young D, Barbosa M, Mann M, Manning A, et al. (1997) IKK-1 and IKK-2: cytokine-activated I
B kinases essential for NF-
B activation. Science (Wash DC) 281: 860-866.
Nishiya T, Uehara T, Kaneko M, and Nomura Y (2000) Involvement of nuclear factor-
B (NF-
B) signaling in the expression of inducible nitric oxide synthase (iNOS) gene in rat C6 glioma cells. Biochem Biophys Res Commun 275: 268-273.[CrossRef][Medline]
Nishiya T, Uehara T, and Nomura Y (1995) Herbimycin A suppresses NF-
B activation and tyrosine phosphorylation of JAK2 and the subsequent induction of nitric oxide synthase in C6 glioma cells. FEBS Lett 371: 333-336.[CrossRef][Medline]
Nomura Y and Kitamura Y (1993) Inducible nitric oxide synthase in glial cells. Neurosci Res 18: 103-107.[CrossRef][Medline]
O'Mahony A, Lin X, Geleziunas R and Greene WC (2000) Activation of the heterodimeric I
B kinase
(IKK
)-IKK
complex is directional: IKK
regulates IKK
under both basal and stimulated conditions. Mol Cell Biol 20: 1170-1178.
Perkins ND (2000) The Rel/NF-
B family: friend and foe. Trends Biochem Sci 25: 434-440.[CrossRef][Medline]
Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, and Rothe M (1997) Identification and characterization of an I
B kinase. Cell 90: 373-383.[CrossRef][Medline]
Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, and Santoro MG (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I
B kinase. Nature (Lond) 403: 103-108.[CrossRef][Medline]
Rothwarf DM, Zandi E, Natoli G, and Karin M (1998) IKK
is an essential regulatory subunit of the I
B kinase complex. Nature (Lond) 395: 297-300.[CrossRef][Medline]
Schreck R, Rieber P, and Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-
B transcription factor and HIV-1. EMBO (Eur Mol Biol Organ) J 10: 2247-2258.[Medline]
Senga T, Miyazaki K, Machida K, Iwata H, Matsuda S, Nakashima I, and Hamaguchi M (2000) Clustered cysteine residues in the kinase domain of v-Src: critical role for protein stability, cell transformation and sensitivity to herbimycin A. Oncogene 19: 273-279.[CrossRef][Medline]
Stancovski I and Baltimore D (1997) NF-
B activation: the I
B kinase revealed? Cell 91: 299-302.[CrossRef][Medline]
Tanaka S, Uehara T, and Nomura Y (2000) Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J Biol Chem 275: 10388-10393.
Uehara T, Baba I, and Nomura Y (1998) Induction of cytokine-induced neutrophil chemoattractant in response to various stresses in rat C6 glioma cells. Brain Res 790: 284-292.[CrossRef][Medline]
Uehara T, Matsuno J, Kaneko M, Nishiya T, Fujimuro M, Yokosawa H, and Nomura Y (1999) Transient nuclear factor
B (NF-
B) activation stimulated by interleukin-1
may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the I
B
molecule, in C6 glioma cells. Regulation of NF-
B linked to chemokine production. J Biol Chem 274: 15875-15882.
Uehara Y, Fukazawa H, Murakami Y, and Mizuno S (1989) Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 163: 155-158.[CrossRef][Medline]
Woronicz JD, Gao X, Cao Z, Rothe M, and Goeddel DV (1997) I
B kinase-
: NF-
B activation and complex formation with I
B kinase-
and NIK. Science (Wash DC) 281: 866-870.
Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, and Israel A (1998) Complementation cloning of NEMO, a component of the I
B kinase complex essential for NF-
B activation. Cell 93: 1231-1240.[CrossRef][Medline]
Yin MJ, Yamamoto Y, and Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I
B kinase
. Nature (Lond) 396: 77-80.[CrossRef][Medline]
Zandi E, Rothwarf DM, Dalhase M, Hayakawa M, and Karin M (1997) The I
B kinase complex (IKK) contains two kinase subunits, IKK
and IKK
, necessary for I
B phosphorylation and NF-
B activation. Cell 91: 243-252.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
M. K. Pandey, B. Sung, A. B. Kunnumakkara, G. Sethi, M. M. Chaturvedi, and B. B. Aggarwal Berberine Modifies Cysteine 179 of I{kappa}B{alpha} Kinase, Suppresses Nuclear Factor-{kappa}B-Regulated Antiapoptotic Gene Products, and Potentiates Apoptosis Cancer Res., July 1, 2008; 68(13): 5370 - 5379. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-S. Yan, Y. Li, Y. Wang, S.-S. Shen, Y. Gu, H.-B. Wang, G.-W. Qin, and Q. Yu 17-Acetoxyjolkinolide B irreversibly inhibits I{kappa}B kinase and induces apoptosis of tumor cells Mol. Cancer Ther., June 1, 2008; 7(6): 1523 - 1532. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Hao, S. A. Rutherford, B. Low, and H. Tang Suppression of the Phosphorylation of Receptor Tyrosine Phosphatase-{alpha} on the Src-Independent Site Tyrosine 789 by Reactive Oxygen Species Mol. Pharmacol., June 1, 2006; 69(6): 1938 - 1944. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsuruma, T. Nakagawa, N. Morimoto, M. Minami, H. Hara, T. Uehara, and Y. Nomura Glucocorticoid Modulatory Element-binding Protein 1 Binds to Initiator Procaspases and Inhibits Ischemia-induced Apoptosis and Neuronal Injury J. Biol. Chem., April 21, 2006; 281(16): 11397 - 11404. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Gill, J.-E. Murphy, and J. D. Fingeroth Functional Divergence of Kaposi's Sarcoma-Associated Herpesvirus and Related Gamma-2 Herpesvirus Thymidine Kinases: Novel Cytoplasmic Phosphoproteins That Alter Cellular Morphology and Disrupt Adhesion J. Virol., December 1, 2005; 79(23): 14647 - 14659. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||